Stock listing
Copenhagen:NOVOB Novo Nordisk A/S Aktie
Home listing (Copenhagen) of Novo Nordisk A/S
Follow Novo Nordisk A/S into a list and get an email when it puts out news.
Share price · OMXCOP:NOVO_B
264.50 DKK -6.95 (-2.6%)
Close on Nov 20, 2026
- Day range
- 260.35 – 266.15 DKKNov 20, 2026
- Volume
- 4.53M sharesNov 20, 2026
- Market cap
- 881.7B DKKAt the close on Nov 20, 2026 · price × 3.33B shares outstanding
- 52-week range
- 224.25 – 409.95 DKKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- 1.34B DKKMedian day 4.43M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NYSE:NVO | $37.82 USD | -1.05 (-2.7%) | 13,068,177 | $38.44 | $39.12 | $37.75 | $38.87 | Close on Nov 20, 2026 |
| Xetra:NOV | €35.18 EUR | -0.265 (-0.7%) | 199,309 | €35.18 | €35.60 | €34.85 | €35.44 | Close on Nov 20, 2026 |
| TSX:NOVO | $16.72 CAD | -0.58 (-3.4%) | 6,394 | $17.26 | $17.27 | $16.72 | $17.30 | Close on Nov 20, 2026 |
| OTC:NONOF | $37.76 USD | -1.745 (-4.4%) | 9,877 | $37.51 | $39.00 | $37.51 | $39.50 | Close on Nov 20, 2026 |
| Cboe Canada:NVON | $4.17 CAD | -0.07 (-1.7%) | 21,875 | $4.30 | $4.31 | $4.17 | $4.24 | Close on Nov 20, 2026 |
| Frankfurt:NOV | €34.50 EUR | -0.865 (-2.4%) | — | €35.10 | €35.50 | €34.50 | €35.37 | Close on Nov 20, 2026 |
| B3:N1VO34 | 29.00 BRL | +0.12 (+0.4%) | 16,072 | 28.30 | 29.35 | 28.27 | 28.88 | Close on Nov 19, 2026 |
| Frankfurt:NOVA | €34.36 EUR | -0.90 (-2.6%) | 456 | €35.00 | €35.66 | €34.36 | €35.26 | Close on Nov 20, 2026 |
| LSE:0TDD | $38.29 USD | -0.55 (-1.4%) | 73,490 | $38.46 | $39.12 | $38.21 | $38.84 | Close on Nov 20, 2026 |
| Dusseldorf:NOVA | €34.82 EUR | -0.48 (-1.4%) | — | €34.86 | €35.34 | €34.82 | €35.30 | Close on Nov 20, 2026 |
| Hamburg:NOV | €35.27 EUR | -0.125 (-0.4%) | 10 | €34.99 | €35.27 | €34.99 | €35.40 | Close on Nov 20, 2026 |
| Dusseldorf:NOV | €34.72 EUR | -0.645 (-1.8%) | 250 | €34.91 | €35.35 | €34.72 | €35.37 | Close on Nov 20, 2026 |
| Munich:NOV | €35.06 EUR | -1.075 (-3.0%) | — | €35.16 | €35.16 | €35.03 | €36.13 | Close on Nov 20, 2026 |
| Munich:NOVA | €35.16 EUR | -0.96 (-2.7%) | — | €35.16 | €35.16 | €35.16 | €36.12 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXCOP:NOVO_B · DKK, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 264.50 | -6.95 | -2.6% | 265.00 | 266.15 | 260.35 | 4,534,446 | |
| 271.45 | -4.05 | -1.5% | 275.50 | 277.70 | 269.45 | 4,462,338 | |
| 275.50 | -9.75 | -3.4% | 283.80 | 283.80 | 274.05 | 5,920,442 | |
| 285.25 | +6.80 | +2.4% | 283.00 | 288.45 | 282.60 | 5,004,913 | |
| 278.45 | +2.70 | +1.0% | 274.75 | 278.45 | 274.00 | 3,990,600 | |
| 275.75 | +3.05 | +1.1% | 276.90 | 279.65 | 271.20 | 7,230,342 | |
| 272.70 | +1.20 | +0.4% | 271.50 | 274.45 | 270.40 | 4,338,121 | |
| 271.50 | +2.05 | +0.8% | 276.90 | 278.00 | 270.45 | 3,567,454 | |
| 269.45 | -1.80 | -0.7% | 267.00 | 271.15 | 265.60 | 5,243,688 | |
| 271.25 | -13.95 | -4.9% | 282.85 | 282.85 | 268.45 | 8,796,632 | |
| 285.20 | +15.05 | +5.6% | 280.15 | 287.95 | 273.10 | 12,125,742 | |
| 270.15 | -0.05 | 0.0% | 270.45 | 271.00 | 267.15 | 4,426,756 | |
| 270.20 | +4.10 | +1.5% | 264.00 | 270.20 | 263.75 | 3,649,526 | |
| 266.10 | +5.75 | +2.2% | 264.80 | 268.40 | 262.90 | 6,661,279 | |
| 260.35 | +5.35 | +2.1% | 255.70 | 261.50 | 254.75 | 6,307,372 | |
| 255.00 | -4.50 | -1.7% | 258.70 | 260.65 | 254.95 | 5,015,221 | |
| 259.50 | -0.95 | -0.4% | 260.45 | 262.25 | 258.20 | 4,300,070 | |
| 260.45 | +0.30 | +0.1% | 260.70 | 263.30 | 259.85 | 3,209,440 | |
| 260.15 | -4.60 | -1.7% | 264.60 | 264.60 | 258.50 | 4,168,570 | |
| 264.75 | +3.05 | +1.2% | 260.90 | 264.75 | 260.35 | 4,126,144 | |
| 261.70 | +0.50 | +0.2% | 262.30 | 262.75 | 259.25 | 3,706,533 | |
| 261.20 | +3.20 | +1.2% | 256.95 | 261.20 | 256.60 | 3,653,012 | |
| 258.00 | -1.60 | -0.6% | 260.00 | 260.65 | 255.95 | 288,062 | |
| 259.60 | -3.85 | -1.5% | 261.00 | 262.15 | 259.35 | 5,455,009 | |
| 263.45 | +7.50 | +2.9% | 255.50 | 263.45 | 254.25 | 6,214,304 | |
| 255.95 | -0.70 | -0.3% | 253.25 | 258.00 | 252.30 | 3,878,749 | |
| 256.65 | +0.25 | +0.1% | 258.45 | 260.40 | 255.80 | 4,055,271 | |
| 256.40 | +1.15 | +0.5% | 257.15 | 259.80 | 255.65 | 4,112,518 | |
| 255.25 | +5.35 | +2.1% | 252.50 | 257.80 | 252.00 | 5,041,888 | |
| 249.90 | -4.00 | -1.6% | 253.90 | 254.95 | 249.90 | 3,784,117 | |
| 253.90 | +8.35 | +3.4% | 248.25 | 254.25 | 247.50 | 6,162,474 | |
| 245.55 | -1.25 | -0.5% | 251.45 | 252.00 | 244.50 | 4,938,995 | |
| 246.80 | -1.95 | -0.8% | 249.05 | 249.15 | 243.15 | 5,784,986 | |
| 248.75 | -1.25 | -0.5% | 246.60 | 250.50 | 246.15 | 4,305,929 | |
| 250.00 | -3.20 | -1.3% | 250.70 | 252.55 | 247.95 | 5,772,781 | |
| 253.20 | +1.55 | +0.6% | 249.75 | 255.15 | 249.10 | 7,931,061 | |
| 251.65 | -0.60 | -0.2% | 252.50 | 254.80 | 250.85 | 4,664,422 | |
| 252.25 | -0.75 | -0.3% | 254.30 | 255.90 | 251.40 | 4,679,253 | |
| 253.00 | 0.00 | 0.0% | 254.00 | 255.00 | 252.00 | 3,906,196 | |
| 253.00 | +0.75 | +0.3% | 250.00 | 254.20 | 247.05 | 7,386,035 | |
| 252.25 | -6.55 | -2.5% | 256.00 | 260.45 | 252.25 | 5,754,249 | |
| 258.80 | -1.20 | -0.5% | 259.05 | 260.70 | 255.40 | 7,392,648 | |
| 260.00 | -21.55 | -7.7% | 284.30 | 284.30 | 257.90 | 13,903,990 | |
| 281.55 | +2.20 | +0.8% | 281.00 | 284.70 | 279.20 | 9,279,685 | |
| 279.35 | +6.75 | +2.5% | 273.40 | 279.90 | 272.25 | 5,230,534 | |
| 272.60 | -3.30 | -1.2% | 275.90 | 280.40 | 272.10 | 4,157,196 | |
| 275.90 | -4.50 | -1.6% | 282.50 | 283.05 | 275.40 | 3,106,990 | |
| 280.40 | +3.95 | +1.4% | 277.15 | 283.65 | 277.10 | 3,582,380 | |
| 276.45 | -9.85 | -3.4% | 282.00 | 283.95 | 275.50 | 5,300,727 | |
| 286.30 | -2.60 | -0.9% | 287.55 | 290.45 | 285.70 | 3,211,322 | |
| 288.90 | -3.10 | -1.1% | 290.00 | 291.45 | 287.80 | 4,429,973 | |
| 292.00 | -6.95 | -2.3% | 297.00 | 298.20 | 291.65 | 3,892,795 | |
| 298.95 | +0.05 | 0.0% | 297.10 | 299.40 | 296.55 | 1,797,150 | |
| 298.90 | -2.65 | -0.9% | 304.00 | 305.45 | 296.70 | 3,129,002 | |
| 301.55 | -0.10 | 0.0% | 301.65 | 309.90 | 299.95 | 4,776,219 | |
| 301.65 | +7.75 | +2.6% | 293.40 | 302.70 | 292.65 | 4,095,568 | |
| 293.90 | +1.50 | +0.5% | 290.90 | 297.80 | 290.90 | 3,512,788 | |
| 292.40 | -3.10 | -1.0% | 293.45 | 294.25 | 289.85 | 5,554,486 | |
| 295.50 | +0.25 | +0.1% | 294.60 | 301.10 | 294.00 | 4,184,104 | |
| 295.25 | -9.70 | -3.2% | 300.50 | 301.05 | 293.45 | 5,695,327 | |
| 304.95 | -2.85 | -0.9% | 311.00 | 314.85 | 304.85 | 3,461,972 | |
| 307.80 | +8.55 | +2.9% | 302.90 | 309.35 | 302.60 | 4,451,386 | |
| 299.25 | -1.60 | -0.5% | 298.15 | 304.45 | 298.00 | 3,241,705 | |
| 300.85 | +4.70 | +1.6% | 296.10 | 300.85 | 294.25 | 3,754,463 | |
| 296.15 | -3.30 | -1.1% | 299.40 | 301.10 | 295.80 | 3,084,254 |
Splits
3 splits since 2007 · OMXCOP:NOVO_B · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 2-for-1 | Split | |
| 5-for-1 | Split | |
| 2-for-1 | Split |
- Ticker
- Copenhagen:NOVO_B
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Copenhagen
- Currency
- DKK
What changed lately
Latest news release · Sep 29, 2026
Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596
Latest earnings call · Aug 5, 2026
Novo Nordisk (Copenhagen:NOVO B) Q2 2026 Earnings Call
Replay and transcript
Latest deck · Sep 21, 2026
Investor Day (September 2026)
Investor day · 14 slides
Latest news
Novo and Hengrui Pharma enter exclusive license agreement for once-weekly oral GLP-1/GIP dual receptor agonist HRS-1596
Sep 29, 2026
Closed 251.65 (-0.2%) on Sep 29, 2026
Highlights to be presented at Novo’s Capital Markets Day 2026
Sep 21, 2026
Closed 260.00 (-7.7%) on Sep 21, 2026
Novo Nordisk enters next chapter to bring better health to more people, supported by ‘Novo’ rebrand and updated corporate culture
Sep 14, 2026
Closed 280.40 (+1.4%) on Sep 14, 2026
Novo Nordisk A/S: IT Security incident at Novo Nordisk
Jun 11, 2026
Closed 287.25 (+1.7%) on Jun 12, 2026
Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK
Jun 11, 2026
Closed 287.25 (+1.7%) on Jun 12, 2026
Novo Nordisk introduces updated Rybelsus® tablet formulation in Canada for adults living with type 2 diabetes
Jun 9, 2026
Closed 269.50 (-0.9%) on Jun 9, 2026
Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care
Jun 3, 2026
Closed 271.80 (-2.1%) on Jun 3, 2026
Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association's 2026 Scientific Sessions
May 27, 2026
Closed 290.10 (+0.9%) on May 27, 2026
Novo Nordisk Introduces Extra Savings for Canadians Who Choose Ozempic®
May 26, 2026
Closed 287.40 (-0.6%) on May 26, 2026
Novo Nordisk A/S on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 85 in the last 12 months · 113 in all · newest Sep 29, 2026 · oldest 2025
- Calls
- 26 calls with a replay · 26 with a transcript · latest Aug 5, 2026
- Decks
- 230 decks · latest Sep 21, 2026
Where Novo Nordisk A/S is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Copenhagen:NOVOB · Home listing · This page | Copenhagen | Denmark | DKK |
| NYSE:NVO | NYSE | United States | USD |
| Xetra:NOV | Xetra | Germany | EUR |
| gettex:NOV | gettex | Germany | EUR |
| Tradegate:NOV | Tradegate | Germany | EUR |
| TSX:NOVO | TSX | Canada | CAD |
| LS Exchange:A3EU6F | LS Exchange | Germany | EUR |
| Aquis:NOVOBC | Aquis | United Kingdom | DKK |
| SET:NOVOB80 | SET | Thailand | THB |
| gettex:NOVA | gettex | Germany | EUR |
| LSIN:0QIU | LSIN | United Kingdom | DKK |
| OTC:NONOF | OTC | United States | USD |
| BMV:NVON | BMV | Mexico | MXN |
| Cboe Canada:NVON | Cboe Canada | Canada | CAD |
| Tradegate:NOVA | Tradegate | Germany | EUR |
| Stuttgart:NOV | Stuttgart | Germany | EUR |
| Frankfurt:NOV | Frankfurt | Germany | EUR |
| Lang & Schwarz:A3EU6F | Lang & Schwarz | Germany | EUR |
| B3:N1VO34 | B3 | Brazil | BRL |
| Cboe Canada:NOVO | Cboe Canada | Canada | CAD |
| BOATS:NVO | BOATS | United States | USD |
| GPW:NVO | GPW | Poland | PLN |
| LS Exchange:866931 | LS Exchange | Germany | EUR |
| Aquis:NOVOBC | Aquis | United Kingdom | DKK |
| Turquoise:NOVOBC | Turquoise | United Kingdom | DKK |
| BMV:NOVOBN | BMV | Mexico | MXN |
| Frankfurt:NOVA | Frankfurt | Germany | EUR |
| LSE:0TDD | LSE | United Kingdom | USD |
| BX Swiss:NOV | BX Swiss | Switzerland | CHF |
| VIE:NNO2 | Vienna | Austria | EUR |
| BX Swiss:NVO | BX Swiss | Switzerland | CHF |
| Aquis:NOVD | Aquis | United Kingdom | EUR |
| Lang & Schwarz:866931 | Lang & Schwarz | Germany | EUR |
| Dusseldorf:NOVA | Dusseldorf | Germany | EUR |
| BIVA:NOVOBN | BIVA | Mexico | MXN |
| Hamburg:NOV | Hamburg | Germany | EUR |
| Stuttgart:NOVA | Stuttgart | Germany | EUR |
| Aquis:NOVD | Aquis | United Kingdom | EUR |
| Frankfurt:NOV1 | Frankfurt | Germany | EUR |
| BCBA:NVO | BCBA | Argentina | ARS |
| Dusseldorf:NOV | Dusseldorf | Germany | EUR |
| Hanover:NOV | Hanover | Germany | EUR |
| Munich:NOV | Munich | Germany | EUR |
| Munich:NOVA | Munich | Germany | EUR |
| Frankfurt:NOV0 | Frankfurt | Germany | EUR |
| BSESOF:NOV | BSESOF | Bulgaria | EUR |
| Hamburg:NOVA | Hamburg | Germany | EUR |
| BCBA:NVOC | BCBA | Argentina | USD |
| BCBA:NVOD | BCBA | Argentina | USD |
| BCBA:NVO.CI | BCBA | Argentina | ARS |
Valuation
P/E 7.8× against a median of 21.7×: 2nd lowest of 11 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- 969.8B DKK
- P/E
- 7.8×
- EV/sales
- 2.9×
- EV/EBITDA
- 5.5×
- Price/book
- 4.0×
- Gross margin
- 82.0%
- Operating margin
- 46.2%
- Net margin
- 33.9%
- Debt to equity
- 0.6×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Novo Nordisk A/S Class B · OMXCOP:NOVO_B | US$129.4B | US$142.3B | 7.8× | 2.9× | 5.5× | 4.0× | 33.9% | 0.6× | n/a |
| Merck & Company, Inc. · NYSE:MRK | US$329.7B | US$373.8B | 134× | 5.5× | n/a | 7.3× | 3.6% | 1.2× | 0.28 |
| Novartis AG · SIX:NOVN | US$287.4B | US$304.7B | 20.6× | n/a | n/a | 6.2× | n/a | 0.6× | n/a |
| AstraZeneca PLC · LSE:AZN | US$272.1B | US$298.0B | 24.6× | 4.8× | 14.1× | 5.3× | 17.7% | 0.7× | n/a |
| Pfizer, Inc. · NYSE:PFE | US$156.2B | US$207.8B | 38.7× | 3.3× | 9.6× | 1.8× | 6.3% | 0.7× | 0.29 |
| Vertex Pharmaceuticals Incorporated · NASDAQ:VRTX | US$130.6B | US$128.8B | 32.8× | 9.9× | 28.4× | 6.3× | 30.7% | 0.2× | 0.47 |
| Bristol-Myers Squibb Company · NYSE:BMY | US$120.2B | US$151.3B | 13.0× | 3.0× | n/a | 5.1× | 18.5% | 1.9× | 0.26 |
| Sanofi SA · EURONEXT:SAN | US$111.7B | US$126.9B | 14.6× | 2.3× | 4.7× | 1.4× | 13.9% | 0.3× | n/a |
| GSK plc · LSE:GSK | US$96.63B | US$123.8B | 17.0× | 2.8× | 9.3× | 3.9× | 13.0% | 1.3× | n/a |
| argenx SE · EURONEXT:ARGX | US$58.86B | US$53.72B | 22.8× | 6.5× | n/a | 7.0× | 31.4% | 0.0× | n/a |
| Roche Holding Ltd · SIX:RO | US$51.16B | US$77.45B | 3.3× | 1.1× | 2.9× | 1.3× | 20.9% | 1.0× | n/a |
| Median of the others | US$125.4B | US$140.0B | 21.7× | 3.3× | 9.4× | 5.2× | 17.7% | 0.7× | 0.29 |
Forecasts
Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.
- Price target
- 299.91 DKK · Analysts' mean
- EPS, year to Dec 2026
- 22.83 · 22 analysts
- Revenue, year to Dec 2026
- 311B · 27 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Elin Jäger | Senior Vice President, Chief of Staff to CEO, Transformation & Sustainability |
| Hong Chow | Executive Vice President, Chief Financial Officer |
| Thomas Rask Nielsen | Senior Vice President, Group General Counsel & Legal, Ethics & Compliance, Business Assurance, IP & Security |
| Emil Kongshøj Larsen | Executive Vice President, Head of North America |
| Karsten Munk Knudsen | Executive Vice President, Global Operations |
| Kasper Bødker Mejlvang | Executive Vice President, Global Manufacturing & Supply |
| Martin Holst Lange | Executive Vice President, Global Commercial Strategy and Corporate Affairs |
| Maziar Mike Doustdar | Executive Vice President, Global R&D |
| Tania Sabroe | Executive Vice President, People, Organisation & Corporate Affairs |
| Thilde Hummel Bøgebjerg | Executive Vice President, Global Marketing |
| Jamey Millar | Executive Vice President, US Operations |
Board
| Director | Role |
|---|---|
| Cees de Jong | Vice chair of the Board of Directors, chair of the Remuneration Committee, member of the Chair Committee, and member of the Audit Committee |
| Britt Meelby Jensen | Member of the Board of Directors, member of the Remuneration Committee and member of the Research & Development Committee |
| Désirée Jantzen Asgreen | Member of the Board of Directors (employee representative) and member of the Research & Development Committee |
| Elisabeth Dahl Christensen | Member of the Board of Directors (employee representative) and member of the Remuneration Committee |
| Helena Saxon | Member of the Board of Directors, member of the People & Governance Committee and member of the Audit Committee |
| Jan van de Winkel | Member of the Board of Directors and chair of the Research & Development Committee |
| Kasim Kutay | Member of the Board of Directors, member of the Research & Development Committee |
| Mette Bøjer Jensen | Member of the Board of Directors (employee representative), member of the Audit Committee |
| Ramona Sequeira | Member of the Board of Directors, member of the Remuneration Committee and member of the Research & Development Committee |
| Semsi Kilic Madsen | Member of the Board of Directors (employee representative) and member of the People & Governance Committee |
| Stephan Engels | Member of the Board of Directors, chair of the Audit Committee and member of the People & Governance Committee |
Events
- Next results
- Feb 3, 2027 (expected)
Calls
| Call | When | Status |
|---|---|---|
| Novo Nordisk (Copenhagen:NOVO B) Q2 2026 Earnings Call | Wed, Aug 05, 2026 · 7:00 AM ET | Replay |
| Novo Nordisk (Copenhagen:NOVO B) Q1 2026 Earnings Call | Wed, May 06, 2026 · 7:00 AM ET | Replay |
| Novo Nordisk (Copenhagen:NOVO B) Q4 2025 Earnings Call | Wed, Feb 04, 2026 · 7:00 AM ET | Replay |
| Novo Nordisk (Copenhagen:NOVO B) Q3 2025 Earnings Call | Wed, Nov 05, 2025 · 7:00 AM ET | Replay |
| Novo Nordisk (Copenhagen:NOVO B) Q2 2025 Earnings Call | Wed, Aug 06, 2025 · 7:00 AM ET | Replay |
| Novo Nordisk (Copenhagen:NOVO B) Q1 2025 Earnings Call | Wed, May 07, 2025 · 7:00 AM ET | Replay |
| Novo Nordisk (Copenhagen:NOVO B) Q4 2024 Earnings Call | Wed, Feb 05, 2025 · 11:00 AM ET | Replay |
| Novo Nordisk (Copenhagen:NOVO B) Q3 2024 Earnings Call | Wed, Nov 06, 2024 · 7:00 AM ET | Replay |
| Novo Nordisk (Copenhagen:NOVO B) Q2 2024 Earnings Call | Wed, Aug 07, 2024 · 7:00 AM ET | Replay |
| Novo Nordisk (Copenhagen:NOVO B) Q1 2024 Earnings Call | Thu, May 02, 2024 · 8:30 AM ET | Replay |
All 26 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · Before open | +5.6% |
| Q2 2026 | Aug 4, 2026 · After close | −4.3% |
| Q1 2026 | May 5, 2026 · After close | +2.5% |
| Q4 2025 | Feb 3, 2026 · After close | −17.2% |
| Q3 2025 | Nov 5, 2025 · Before open | −4.5% |
| Q2 2025 | Aug 6, 2025 · Before open | −5.4% |
| Q1 2025 | May 7, 2025 · Before open | +1.3% |
| Q4 2024 | Feb 4, 2025 · After close | +4.5% |
| Q3 2024 | Nov 6, 2024 · Before open | +0.6% |
| Q2 2024 | Aug 7, 2024 · Before open | −6.7% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 2, 2024 · Before open | −2.7% |
| Q4 2023 | Jan 31, 2024 · Before open | +3.6% |
| Q3 2023 | Nov 2, 2023 · Before open | +3.2% |
| Q2 2023 | Aug 9, 2023 · After close | −1.2% |
| Q1 2023 | May 4, 2023 · Before open | −2.6% |
| Q4 2022 | Feb 1, 2023 · Before open | −0.1% |
| Q3 2022 | Nov 2, 2022 · Before open | +7.4% |
| Q2 2022 | Aug 3, 2022 · After close | +1.0% |
| Q1 2022 | Apr 29, 2022 · Before open | +5.4% |
| Q4 2021 | Feb 1, 2022 · After close | +4.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Day (September 2026) | Investor day | 14 slides | Sep 21, 2026 |
| Investor Day (September 2026) | Investor day | 16 slides | Sep 21, 2026 |
| Investor Day (September 2026) | Investor day | 14 slides | Sep 21, 2026 |
| Investor Day (September 2026) | Investor day | 13 slides | Sep 21, 2026 |
| Investor Day (September 2026) | Investor day | 13 slides | Sep 21, 2026 |
| Investor Day (September 2026) | Investor day | 20 slides | Sep 21, 2026 |
| Investor Day (September 2026) | Investor day | 13 slides | Sep 21, 2026 |
| Investor Day (September 2026) | Investor day | 16 slides | Sep 21, 2026 |
| Investor Day (September 2026) | Investor day | 14 slides | Sep 21, 2026 |
| Investor Day (September 2026) | Investor day | 16 slides | Sep 21, 2026 |
Show 50 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 2026 Earnings Presentation | Earnings | 85 slides | Aug 5, 2026 |
| Investor Presentation (June 2026) | Investor deck | 28 slides | Jun 7, 2026 |
| Technical Presentation (May 2026) | Technical | 24 slides | May 7, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 84 slides | May 6, 2026 |
| Shareholder Meeting (March 2026) | Shareholder meeting | 51 slides | Mar 26, 2026 |
| Technical Presentation (March 2026) | Technical | 18 slides | Mar 18, 2026 |
| FY2025 Earnings Presentation | Earnings | 121 slides | Feb 4, 2026 |
| 67th ASH Annual Meeting and Exposition 2025 | Conference | 17 slides | December 2025 |
| Shareholder Meeting (November 2025) | Shareholder meeting | 20 slides | Nov 14, 2025 |
| Q3 2025 Earnings Presentation | Earnings | 138 slides | Nov 5, 2025 |
| Merger or Acquisition (October 2025) | Merger or acquisition | 8 slides | Oct 9, 2025 |
| Technical Presentation (September 2025) | Technical | 5 slides | Sep 15, 2025 |
| European Society of Cardiology (ESC) Congress together with World Congress of Cardiology 2 (August 2025) | Conference | 15 slides | Aug 31, 2025 |
| H1 2025 Earnings Presentation | Earnings | 180 slides | Aug 6, 2025 |
| Investor Day (June 2025) | Investor day | 58 slides | Jun 22, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 173 slides | May 7, 2025 |
| Shareholder Meeting (March 2025) | Shareholder meeting | 53 slides | Mar 27, 2025 |
| Shareholder Meeting (March 2025) | Shareholder meeting | 53 slides | Mar 27, 2025 |
| Shareholder Meeting (February 2025) | Shareholder meeting | 18 slides | Feb 27, 2025 |
| FY2024 Earnings Presentation | Earnings | 164 slides | Feb 5, 2025 |
| Technical Presentation (2025) | Technical | 19 slides | 2025 |
| Technical Presentation (2025) | Technical | 15 slides | 2025 |
| Q3 2024 Earnings Presentation | Earnings | 163 slides | Nov 6, 2024 |
| Technical Presentation (September 2024) | Technical | 13 slides | Sep 5, 2024 |
| H1 2024 Earnings Presentation | Earnings | 159 slides | Aug 7, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 159 slides | May 2, 2024 |
| Shareholder Meeting (March 2024) | Shareholder meeting | 55 slides | Mar 21, 2024 |
| Shareholder Meeting (March 2024) | Shareholder meeting | 55 slides | Mar 21, 2024 |
| Investor Day (March 2024) | Investor day | 11 slides | Mar 8, 2024 |
| Investor Day (March 2024) | Investor day | 18 slides | Mar 7, 2024 |
| Investor Day (March 2024) | Investor day | 10 slides | Mar 7, 2024 |
| Investor Day (March 2024) | Investor day | 10 slides | Mar 7, 2024 |
| Investor Day (March 2024) | Investor day | 13 slides | Mar 7, 2024 |
| Investor Day (March 2024) | Investor day | 17 slides | Mar 7, 2024 |
| Investor Day (March 2024) | Investor day | 15 slides | Mar 7, 2024 |
| Investor Day (March 2024) | Investor day | 10 slides | Mar 7, 2024 |
| Investor Day (March 2024) | Investor day | 10 slides | Mar 7, 2024 |
| Investor Day (March 2024) | Investor day | 24 slides | Mar 7, 2024 |
| Investor Day (March 2024) | Investor day | 24 slides | Mar 7, 2024 |
| Investor Day (March 2024) | Investor day | 22 slides | Mar 7, 2024 |
This page holds 50 of 230 decks. Open Decks
Financials
Annual, in DKK
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 309.1B | 290.4B | 232.3B | 177.0B | 140.8B | 126.9B | 122.0B | 111.8B | 111.7B | 111.8B |
| Cost of revenue | 58.8B | 44.5B | 35.8B | 28.4B | 23.7B | 20.9B | 20.1B | 17.6B | 17.6B | 17.2B |
| Gross profit | 250.3B | 245.9B | 196.5B | 148.5B | 117.1B | 106.0B | 101.9B | 94.2B | 94.1B | 94.6B |
| Research and development | 52.0B | 48.1B | 32.4B | 24.0B | 17.8B | 15.5B | 14.2B | 14.8B | 14.0B | 14.6B |
| Selling, general and administrative | 5.97B | 5.28B | 61.6B | 4.47B | 4.05B | 3.96B | 4.01B | 3.92B | 3.78B | 3.96B |
| Operating income | 127.7B | 128.3B | 102.6B | 74.8B | 58.6B | 54.1B | 52.5B | 47.2B | 49.0B | 48.4B |
| Depreciation and amortization | 14.7B | 8.54B | 9.41B | 7.36B | 6.03B | 5.75B | 5.66B | 3.92B | 3.18B | 3.19B |
| EBITDA | 142.3B | 136.9B | 112.0B | 82.2B | 64.7B | 59.9B | 58.1B | 51.2B | 52.1B | 51.6B |
| Interest expense | 6.78B | 7.35B | 845.0M | 378.0M | 2.45B | 390.0M | 220.0M | 85.0M | 90.0M | 65.0M |
| Income before tax | 130.5B | 127.2B | 104.7B | 69.1B | 59.1B | 53.1B | 48.6B | 47.6B | 48.7B | 47.8B |
| Income tax | 28.1B | 26.2B | 21.0B | 13.5B | 11.3B | 11.0B | 9.60B | 8.99B | 10.6B | 9.87B |
| Net income | 102.4B | 101.0B | 83.7B | 55.5B | 47.8B | 42.1B | 39.0B | 38.6B | 38.1B | 37.9B |
| Earnings per share, basic | 23.06 | 22.67 | 18.67 | 12.22 | 10.37 | 9.00 | 8.19 | 7.97 | 7.69 | 7.48 |
| Earnings per share, diluted | 23.03 | 22.63 | 18.62 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 26.5B | 15.7B | 14.4B | 12.7B | 10.7B | 12.8B | 15.5B | 15.6B | 18.9B | 18.7B |
| Short-term investments | 498.0M | 10.7B | 15.8B | 10.9B | 6.76B | 0 | 2.30B | 2.01B | ||
| Receivables | 70.9B | 71.9B | 64.8B | 57.5B | 46.8B | 32.2B | 29.2B | 26.9B | 23.6B | 24.2B |
| Inventory | 49.6B | 40.8B | 31.8B | 24.4B | 19.6B | 18.5B | 17.6B | 16.3B | 15.4B | 14.3B |
| Current assets | 172.5B | 161.8B | 139.6B | 108.2B | 85.6B | 65.8B | 62.5B | 59.1B | 60.1B | 59.8B |
| Property, plant and equipment | 208.4B | 161.7B | 66.7B | 55.4B | 50.3B | 50.6B | 41.9B | 35.2B | 30.2B | |
| Goodwill | 19.8B | 20.0B | 4.46B | 5.09B | 4.35B | 0 | ||||
| Total assets | 542.9B | 465.6B | 314.5B | 241.3B | 194.5B | 144.9B | 125.6B | 110.8B | 102.4B | 97.5B |
| Accounts payable | 19.8B | 17.1B | 25.6B | 15.6B | 8.87B | 5.72B | 6.36B | 6.76B | 5.61B | 6.01B |
| Current liabilities | 215.7B | 217.6B | 169.7B | 120.9B | 99.5B | 70.3B | 59.0B | 54.2B | 47.1B | 47.4B |
| Long-term debt | 118.9B | 89.7B | 16.0B | 20.8B | 9.65B | |||||
| Total debt | 131.0B | 102.8B | 27.0B | 25.8B | 26.6B | 10.4B | 4.48B | 515.0M | 1.69B | 229.0M |
| Total liabilities | 348.9B | 322.1B | 207.9B | 157.8B | 123.8B | 81.6B | 68.0B | 58.9B | 52.5B | 52.3B |
| Shareholders' equity | 194.0B | 143.5B | 106.6B | 83.5B | 70.7B | 63.3B | 57.6B | 51.8B | 49.8B | 45.3B |
| Shares outstanding | 4.45B | 4.46B | 4.46B | 4.54B | 4.61B | 4.68B | 4.76B | 4.85B | 4.96B | 5.07B |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 119.1B | 121.0B | 108.9B | 78.9B | 55.0B | 52.0B | 46.8B | 44.6B | 41.2B | 48.3B |
| Capital spending | -60.1B | -47.2B | -25.8B | -14.8B | -7.38B | -22.1B | -11.2B | -12.4B | -8.65B | -8.27B |
| Free cash flow | 59.0B | 73.8B | 83.1B | 64.1B | 47.6B | 29.9B | 35.6B | 32.2B | 32.5B | 40.0B |
| Cash from investing | -79.2B | -128.9B | -43.9B | -24.9B | -31.6B | -22.4B | -11.5B | -12.1B | -6.57B | -6.79B |
| Cash from financing | -28.4B | 8.73B | -63.2B | -51.8B | -25.5B | -32.2B | -35.5B | -34.5B | -35.7B | -38.9B |
| Dividends paid | -51.8B | -44.1B | -31.8B | -25.3B | -21.5B | -20.1B | -19.4B | -19.0B | -18.8B | -23.8B |
| Share buybacks | -1.39B | -20.2B | -29.9B | -24.1B | -19.4B | -16.9B | -15.3B | -15.6B | -16.8B | -15.1B |
| Change in cash | 11.5B | 808.0M | 1.86B | 1.93B | -1.51B | -3.19B | -218.0M | -1.53B | -1.30B | 2.61B |
Cap table
Built by 6ix from Novo Nordisk A/S Class B’s releases
- Common shares
- 3,333,483,124
- Fully diluted
- 3,333,483,124
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 3,333,483,124 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 3,333,483,124 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Britt Meelby Jensen | Member of the Board of Directors, member of the Remuneration Committee and member of the Research & Development Committee · Since at least Feb 20, 2026 |
| Cees de Jong | Vice chair of the Board of Directors, chair of the Remuneration Committee, member of the Chair Committee, and member of the Audit Committee · Since at least Feb 20, 2026 |
| Désirée Jantzen Asgreen | Member of the Board of Directors (employee representative) and member of the Research & Development Committee · Since at least Nov 5, 2026 |
| Elin Jäger | Senior Vice President, Chief of Staff to CEO, Transformation & Sustainability · Since at least Nov 14, 2025 |
| Elisabeth Dahl Christensen | Member of the Board of Directors (employee representative) and member of the Remuneration Committee · Since at least Nov 13, 2025 |
| Emil Kongshøj Larsen | Executive Vice President, Head of North America · Since at least Jun 11, 2026 |
| Helena Saxon | Member of the Board of Directors, member of the People & Governance Committee and member of the Audit Committee · Since at least Feb 20, 2026 |
| Hong Chow | Executive Vice President, Chief Financial Officer · Since at least Nov 5, 2026 |
| Jamey Millar | Executive Vice President, US Operations · Since at least Apr 2, 2026 |
| Jan van de Winkel | Member of the Board of Directors and chair of the Research & Development Committee · Since at least Feb 20, 2026 |
All 23 people
| Person | Seat |
|---|---|
| Karsten Munk Knudsen | Executive Vice President, Global Operations · Since at least Nov 5, 2026 |
| Kasim Kutay | Member of the Board of Directors, member of the Research & Development Committee · Since at least Feb 20, 2026 |
| Kasper Bødker Mejlvang | Executive Vice President, Global Manufacturing & Supply · Since at least Mar 2, 2026 |
| Lars Rebien Sørensen | Chair of the Board of Directors, chair of the Chair Committee and the People & Governance Committee · Until Oct 21, 2025 · Past |
| Martin Holst Lange | Executive Vice President, Global Commercial Strategy and Corporate Affairs · Since at least Sep 29, 2026 |
| Maziar Mike Doustdar | Executive Vice President, Global R&D · Since at least Nov 5, 2026 |
| Mette Bøjer Jensen | Member of the Board of Directors (employee representative), member of the Audit Committee · Since at least Nov 13, 2025 |
| Ramona Sequeira | Member of the Board of Directors, member of the Remuneration Committee and member of the Research & Development Committee · Since at least Feb 20, 2026 |
| Semsi Kilic Madsen | Member of the Board of Directors (employee representative) and member of the People & Governance Committee · Since at least Nov 5, 2026 |
| Stephan Engels | Member of the Board of Directors, chair of the Audit Committee and member of the People & Governance Committee · Since at least Feb 20, 2026 |
| Tania Sabroe | Executive Vice President, People, Organisation & Corporate Affairs · Since at least Sep 14, 2026 |
| Thilde Hummel Bøgebjerg | Executive Vice President, Global Marketing · Since at least Nov 5, 2026 |
| Thomas Rask Nielsen | Senior Vice President, Group General Counsel & Legal, Ethics & Compliance, Business Assurance, IP & Security · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Novo Nordisk A/S.